

1 Reevaluating the Role of ACE Inhibitors in Skin Fibrosis Risk: Evidence from
2 Mendelian Randomization

3 Running title: ACEI does not decrease skin fibrosis

4 Yangyang Wei^{1,2,*}, Ziqi Wan^{2,*}, Yiwen Jiang², Zhengye Liu³, Ming Yang^{4,#}, Jieying
5 Tang^{1,#}

6 1. Department of Plastic Surgery, Beijing Tsinghua Changgung Hospital, School of
7 Clinical Medicine, Tsinghua University, Beijing, China.

8 2. Eight-year Program, Peking Union Medical College and Chinese Academy of
9 Medical Sciences, Beijing, China.

10 3. Department of Plastic and Aesthetic Center, The First Affiliated Hospital, School of
11 Medicine, Zhejiang University, Hangzhou, Zhejiang, China.

12 4. Department of Cardiology, Peking Union Medical College Hospital, Chinese
13 Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

14

15 *Contributed equally

16 #Corresponding authors: Dr. Jieying Tang, Department of Plastic Surgery, Beijing
17 Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University,
18 Beijing, China. Tel: 8613811271136. Email: tjya01274@btch.edu.cn

19 Dr. Ming Yang, Department of Cardiology, Peking Union
20 Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union
21 Medical College, Beijing, China. Tel: 86-10-69155005. Email: yangming@pumch.cn

22

23 **Fund:** Beijing Tsinghua Changgung Hospital Fund (Grant No. 12023C1004)

24

25 **Interest Statement**

26 All of us declare that we have no competing interests.

27

28 **Ethical Approval**

29 Not Applicable.

30 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31 **Ethnic Statement**

32 Not Applicable.

33

34 **Data Availability Statement**

35 Sources of full summary GWAS datasets were listed in Supplementary File 2. No new

36 data was generated from recurrent study.

37

38 **Author Contributions**

39 Conceptualization: The study was initially conceptualized by YW, ZW and JT. They
40 developed the research idea and designed the overall framework of the study.

41 Methodology: Methodology was developed by ZW, YJ and ZL. They were
42 responsible for designing and implementing the experimental protocols.

43 Investigation: Investigation and data collection were primarily conducted by YW, ZW
44 and JT. They carried out the experiments and gathered the necessary data.

45 Data Analysis: Data analysis was performed by YW and ZW. They processed the raw
46 data and conducted the statistical analyses.

47 Writing - Original Draft Preparation: The original draft of the manuscript was written
48 by YW and ZW. They prepared the initial version of the paper, including the
49 introduction, methods, results, and discussion sections.

50 Writing - Review & Editing: Review and editing of the manuscript were conducted by
51 YJ, ZL, MY and JT. They reviewed the draft for important intellectual content and
52 made revisions.

53 Funding Acquisition: Funding for the study was secured by MY and JT. They applied
54 for and obtained the necessary grants to support the research.

55 Supervision: Supervision of the entire project was provided by MY and JT. They
56 oversaw the project progress and provided guidance throughout the research.

57 Project Administration: Project administration, including coordination of research
58 activities and maintaining timelines, was managed by MY and JT.

59

60 **Manuscript Count: 3862**

61 **Figure count: 4, Table count: 7**

62

63 **Abstract:**

64 **Background:** Skin fibrosis, characterized by excessive extracellular matrix
65 deposition, leads to hypertrophic scars and keloids, which are both common and often
66 detrimental conditions. Angiotensin-converting enzyme (ACE) inhibitors have shown
67 promise in animal studies and limited clinical trials for reducing scar formation.
68 However, the causal relationship between ACE inhibition and skin fibrosis remains
69 unclear.

70 **Methods:** This study employed two-sample Mendelian randomization (MR) analysis
71 to investigate the causal effect of ACE inhibition on skin fibrotic diseases. We utilized
72 genetic variants associated with serum ACE levels, ACE inhibition, and effect of
73 decreasing blood pressure by ACE inhibition as instrumental variables. We analyzed
74 the association between these exposures and the incidence of skin fibrosis,
75 hypertrophic scars, and keloids using various MR methods.

76 **Results:** We found no significant causal relationship between genetically proxied
77 serum ACE levels, or local skin tissue ACE expression and the risk of skin fibrosis,
78 hypertrophic scars, or keloids. Additionally, there was no direct causal relationship
79 between the effect of ACE inhibitors on blood pressure reduction and the risk of skin
80 fibrotic diseases. However, we observed a significant negative association between
81 systolic blood pressure (SBP) and the risk of hypertrophic scars. Conversely, we
82 found a positive association between β -blockers and the risk of skin fibrosis.

83 **Conclusion:** Our findings suggest that ACE inhibitors do not have a direct causal
84 effect on the risk of skin fibrotic diseases, including hypertrophic scars and keloids.
85 This challenges the potential of ACE inhibitors as a therapeutic option for preventing
86 or treating these conditions.

87

88 **Keywords:** skin fibrosis, angiotensin-converting enzyme, Mendelian Randomization

89

90 **Introduction**

91 Skin fibrosis involves the deposition of extracellular matrix of dermis, a process that
92 can occur in all kinds of wound healing of injuries.¹ Hypertrophic scars and keloids
93 are two common types of excessive scar caused by skin fibrosis. Hypertrophic scar is
94 that scar proliferation stays within the limits of the edges of the initial scar, whereas
95 keloid is characterized by pseudo-tumor proliferation extending over the edges of the
96 initial wound.^{1,2} These conditions are highly prevalent in population, affecting
97 patients with all kinds of skin wounds including surgical ones. Excessive scars can
98 lead to unexpected changes in appearance, causing pain and functionally impairing
99 patients' quality of life. Current conservative treatments for excessive scarring include
100 cryotherapy, corticosteroid injections or tapes, chemotherapy and surgery.¹ Few
101 interventions target the molecular mechanism specifically. Mechanisms of skin
102 fibrosis are not completely understood, involving intricate pathways such as
103 inflammatory reactions and hormone regulation.³

104 Angiotensin-converting enzyme (ACE) is a well-known molecule that can increase
105 blood pressure by converting angiotensin I to angiotensin II within renin-angiotensin
106 system (RAS).⁴ Angiotensin II can bind to the Type I angiotensin receptor (AT1
107 receptor) and initiate the complex downstream effects. The serum ACE has been
108 demonstrated to be critical in the development and progression of fibrosis in multiple
109 organs, including heart, liver, and kidney.⁵⁻⁹ Effects of angiotensin II include the
110 increase of collagen and fibronectin synthesis, which are ultimately associated with
111 fibrosis in different organs. Given its pivotal role in the regulation of RAS, ACE has
112 been inferred to be a therapeutic potential target for skin fibrosis due to its effects on
113 inflammatory reaction and homeostasis of skin healing.⁵ Animal studies have
114 provided evidence that ACE gene deficiency decreases scar formation in rats
115 effectively.^{11,12} A study on rabbits also demonstrated that oral ACE inhibitor
116 (Enalapril) effectively decreased hypertrophic scars on rabbit ears.¹³ And several
117 clinical researches reported the effectiveness of ACE inhibitors in decreasing the
118 formation of excessive scars. A retrospective chart review study on bilateral breast
119 reduction surgery (n = 961) discovered patients with an ACE inhibitors or angiotensin

120 receptor blocker (ARB) exhibited a significantly lower incidence of being diagnosed
121 as hypertrophic scar.¹⁴ Furthermore, in another double-blind clinical trial conducted
122 in Iran population (n = 30), patients treated with local topical Enalapril exhibited
123 hypertrophic scars with significantly smaller mean thickness than the placebo-treated
124 ones, along with a significantly lower mean itching score.¹⁵ However, the sample
125 sizes of the clinical trial were insufficiently large and only involved Iran population.
126 The researches were limited by study design.¹⁶

127 Mendelian randomization is a method to explore the causal effect of two traits
128 (exposure and outcome) via genetic instrumental variants (IVs).^{17, 18} It holds three
129 assumptions: 1) IVs are extensively associated with exposure; 2) There are no
130 confounders between the instruments and outcome; 3) IVs' effect on outcome can
131 only be exerted via exposure. MR provides a convenient method for exploring the
132 causal relationship between phenotypes with evidence of nearly the same level as
133 randomized controlled trial (RCT) when conducting RCTs is challenging. However,
134 there has not been an exploration of the causal relationship between ACE inhibition
135 and diseases related to skin fibrosis using MR analysis.

136 Here we aimed to explore the causal effect of ACE inhibitors (ACEi) on excessive
137 scars related to skin fibrosis, including hypertrophic scar and keloids, by two-sample
138 MR analysis from multiple dimensions. We investigated the causal effects of
139 genetically proxied serum ACE, inhibition of ACE and systolic and diastolic blood
140 pressure (SBP/DBP), respectively, on the incidence of skin fibrosis. And we further
141 explored the causal effects of SBP, DBP, β blockers and calcium channel blockers,
142 angiotensin receptor blockers and excessive scarring related to skin fibrosis.

143

144 **Methods**

145 **Study design**

146 The study design is illustrated in Figure 1. To investigate the causal effect of ACE
147 inhibitors on skin fibrotic diseases, we conducted MR analysis with exposures of
148 serum ACE, genetically-proxied inhibition of serum ACE, and effect of increasing
149 SBP and DBP by ACE, respectively. Furthermore, we employed Summary-based MR

150 analysis (SMR) to explore the causal effect of ACE expression in local skin tissue on
151 skin fibrotic diseases. Considering that the target of Type 1 angiotensin II receptor
152 blockers (ARBs), AT1 receptor is the main downstream receptor of angiotensin II, we
153 investigated causal relationship between ARBs and skin fibrotic diseases. Moreover,
154 considering that blood pressure might be a risk factor of skin fibrotic diseases^{19, 20}, in
155 order to investigate whether the effect of ACE on skin fibrotic diseases is through the
156 blood pressure, we also investigated the causal effect of blood pressure and targets of
157 other anti-hypertension drugs (β blockers and calcium channel blockers, abbreviated
158 as BBs and CCBs) on skin fibrotic diseases through MR analysis. All the genetic IVs
159 were chosen on autosomes in order to avoid sex-specific effects.²¹

160 **Data sources**

161 For serum ACE concentration, we initially utilized single SNP “rs4343” as IV of
162 serum ACE. Rs4343 is located in the *ACE* gene, which is extensively associated with
163 an indel known as *Alu* in the 16th intron and then associated with expression of *ACE*.
164²³ Rs4343 exhibits the strongest association with serum ACE inhibition ($p = 1.53e-213$)
165 among SNPs according to the group of IV proxied serum ACE inhibition.²⁴
166 Additionally, we utilized another group of IVs from a protein quantitative trait locus
167 (pQTL) research of serum ACE of 35,275 individuals with Island ancestry. The
168 population shares a similar age, gender, and BMI structure with the UKB cohort.²²
169 Furthermore, in order to supply more evidence of the causal relationship between
170 serum ACE inhibition and skin fibrotic diseases, we utilized a group of IVs (including
171 rs4343) to proxy serum ACE inhibition from a previous MR study, which was from a
172 pQTL of 4,174 individuals from Genetic Epidemiology Research on Adult Health and
173 Aging.²⁴

174 We initially employed single SNP “rs4291” to proxy the effect of ACE inhibition on
175 decreasing SBP. Rs4291 is located on the promoter of *ACE* gene, which is also
176 extensively associated with the indel *Alu* and exhibits the most significant correlation
177 with the effect of ACE inhibition on decreasing SBP.²⁵ Its effect was from a
178 meta-analysis of GWAS covered 757,601 individuals with European ancestry of UKB
179 individuals and International Consortium of Blood Pressure GWAS.²⁶ Then we

180 utilized another group of IV associated with the decrease effect of SBP by ACE
181 (containing 2 SNPs) extracted by a previous MR study, whose effect was from the
182 mentioned meta-analysis covered 757,601 individuals.²⁴ We accessed GWAS data of
183 SBP and DBP from a previous study encompassing 469,767 and 490,469 individuals
184 within European ancestry in UK Biobank cohort.²⁸ And we selected SNPs that have
185 strong relevance ($p < 5e-8$) with serum ACE according to the mentioned pQTL, and
186 extracted their effects on SBP or DBP from these two GWAS datasets of SBP and
187 DBP. From this set of SNPs, we further included SNPs that also had strong relevance
188 of SBP or DBP ($p < 5e-6$) to proxy the ACE-induced increase of SBP or DBP.

189 For local expression of *ACE* gene in skin tissue, summary data of expression
190 quantitative trait locus research (eQTL) of local tissue was downloaded from GTEx
191 v8 data.²⁹ Considering the influence of sunshine exposure on skin, we employed
192 summary data from suprapubic skin and skin of lower leg to represent skin with and
193 without sunshine exposure respectively.

194 In order to investigate the potential causal effect of anti-hypertension drugs (BBs and
195 CCBs) on skin fibrotic diseases, we extracted IVs proxied the effect of increasing SBP
196 by BB and CCB drug target gene (*ADRB1* for BB, *CACNAID*, *CACNAIF*,
197 *CACNA2D1*, *CACNA2D2*, *CACNAIS*, *CACNB1*, *CACNB2*, *CACNB3*, *CACNB4*,
198 *CACNG1*, and *CACNAIC* for CCB) from a previous study of MR analysis.²⁶ IV for
199 effect of decreasing SBP by ARBs target gene (type 1 angiotensin II receptor, *ATI*)
200 were extracted from another MR study.²⁷ All the effect data to SBP was from the
201 meta-analysis of GWAS covered 757,601 individuals All the detailed information for
202 exposures were listed in Table 1.

203 We employed GWAS datasets for hypertrophic scar, keloid, skin fibrosis, and scar
204 condition (defined as a fibrotic scar that could not be differentiated as keloid or
205 hypertrophic scar).¹ All the data were sourced from populations of European ancestry.
206 Among these data for hypertrophic scar and one data of skin fibrosis and scar
207 condition were from FinnGen, whereas data for keloid and the other data of skin
208 fibrosis and scar condition were from UK Biobank. The detailed information for each
209 dataset was listed in Table 2.^{28, 30}

210 **MR IVs selection**

211 For IVs of multiple SNPs proxied effects of target genes (ACE, target genes for BBs,
212 CCBs and ARBs), we selected SNPs with strong relevance ($p < 5e-8$) to respective
213 exposures. For serum ACE and serum ACE inhibition, we selected SNPs within ± 100
214 kb of *ACE* gene. For effects of decreasing SBP by BBs and CCBs, we selected SNPs
215 within corresponding genes or in the promoters and enhancers.²⁶ IV for ARB was
216 selected in the drug-targeted genes associated with BP at a genome-wide significant
217 level, which was identified in DrugBank.²⁷ Promoter and enhancer regions of
218 corresponding drug targets were identified using the GeneHancer database in the
219 GeneCards online platform. Subsequently, we decreased the linkage disequilibrium of
220 the IVs by clumping on condition that genetic distance $> 10,000$ kb and $r^2 < 0.1$.

221 From the GWAS data of SBP and DBP, we selected SNPs with strong relevance ($p <$
222 $5e-8$).³¹ Then SNPs was clumped on condition that genetic distance $> 10,000$ kb and
223 $r^2 < 0.0001$ to eliminate linkage disequilibrium.

224 For IV of effect of serum ACE on decreasing SBP and DBP, we extracted SNPs with
225 extensive relevance for serum ACE (data from pQTL of serum ACE, $p < 5e-8$) and
226 SBP or DBP (data from GWAS of SBP and DBP, $p < 5e-6$, for no SNP existed on
227 condition that $p < 5e-8$). Then we selected SNPs within ± 100 kb of ACE gene and
228 clumped on condition that genetic distance $> 10,000$ kb and $r^2 < 0.1$ thereby reducing
229 linkage disequilibrium.

230 For all IVs that will be used in MR analysis, we harmonized effects of SNPs on
231 exposure and outcome to ensure effects relative to the same allele and exclude
232 palindromic SNPs with intermediate allele frequencies (> 0.42). In order to avoid
233 potential confounding, we delete SNPs strongly related ($p < 5e-8$) to outcomes (skin
234 fibrosis, hypertrophic scar and keloid) by investigating all the SNPs on PhenoScanner
235 database (<http://www.phenoscaner.medschl.cam.ac.uk/>) .³² For the exposure of SBP,
236 DBP and the effect on SBP/DBP by ACEi, ARB, BBs and CCBs included UKB
237 cohorts, MR analysis with sample overlapping (outcome data from UKB cohorts) was
238 eliminated by checking the sample sources of exposures and outcomes from different
239 cohorts.

240 **Statistics**

241 R (Version 4.3.3, The R Foundation for Statistical Computing Platform, Vienna,
242 Austria) was used to perform MR analysis and subsequent sensitivity analysis. R
243 packages “dplyr”, “TwoSampleMR” (Version 0.6.4) and “ieugwasr”³³ were used to
244 input, clump and analyze data. To explore the causal relationship of exposures and
245 outcomes, when only one SNP existed in IV, we used method Wald ratio, while when
246 two or more SNPs existed, we used method inverse variance weighted (IVW)
247 including random effects IVW (IVW-MRE) and fixed effects IVW (IVW-FE).³⁴ In
248 order to obtain more reference, we performed MR analysis by the weighted-median³⁵,
249 MR Egger³⁶, simple-mode and weighted-mode method as secondary analysis
250 methods. In MR analysis between drug targets (ACEi, ARBs, BBs and CCBs), we
251 didn't employ the MR Egger due to the confounding effects of IVs against the
252 INSIDE assumptions of MR Egger. Cochran's Q statistic was used to estimate the
253 heterogeneity of IVs. If no significant heterogeneity exists ($p_Q < 0.05$), we referred to
254 results from the fixed-effects IVW MR analysis. If significant heterogeneity exists
255 ($p_Q < 0.05$), we referred to results from the random-effects IVW MR analysis. And
256 we tested the pleiotropy of SNPs by the intercept value from the MR Egger method
257³⁶⁻³⁸. The p value less than 0.05 indicated significant pleiotropy. If IVs of exposure
258 were with pleiotropy, the analysis results would be excluded. F statistics were used to
259 evaluate the risk of weak instrument bias. We used formula that $F = (N-k-1)/k*r^2/(1-r^2)$
260 to calculate F. Among those N is the sample size of GWAS research, k is the amount
261 of IVs. For each IV, r^2 was calculated as $2*MAF*(1-MAF)*\beta^2$.³⁹ If F statistics of a
262 group of IVs was above 10, we considered that risk of weak instrument bias of IV can
263 be ignored. An online tool (<https://sb452.shinyapps.io/power/>) was used to calculate
264 the statistical power for MR analysis.⁴⁰

265 Summary-based MR (SMR) analysis was conducted on SMR software (version 1.3.1
266 for Windows system) developed by Zhang et al.⁴¹ The software extracted SNPs
267 within ± 5 Mb of ACE gene and with significant relevance of ACE expression in
268 specific tissue ($p < 5e-8$) from the two eQTL datasets from skin tissue. We excluded
269 SNPs whose allele frequency below 0.01. Then we reduced LD ($R^2 < 0.1$) by referring

270 to the 1000G European data. GWAS datasets of skin fibrotic diseases were used as
271 outcomes in SMR test. Then we conducted HEIDI test to test the heterogeneity. If
272 pHEIDI was above 0.05, we considered the IVs exhibit no significant heterogeneity.
273 Results of SMR with significant heterogeneity were removed.

274

275 **Results**

276 **IVs selection**

277 All the F statistics of IVs were above 10 (listed in Table 1), and the explained variance
278 of IVs were R^2 of 0.025% to 39%. Detailed information including amounts of SNPs,
279 R^2 , F statistics, sample size and source were shown in Table 1. All the SNPs used in
280 MR were listed in Supplementary File 1. MR analysis whose exposure and outcome
281 were with sample overlapping was removed.

282 **Effect of serum ACE or ACE inhibition and skin fibrotic diseases**

283 Our analysis of MR results revealed little causal relationship between serum ACE or
284 ACE inhibition and skin fibrotic diseases. For single SNP (rs4343) proxied serum
285 ACE inhibition, results of Wald ratio showed little causal effect on skin fibrotic
286 diseases (hypertrophic scar: OR = 1.04, 95%CI 0.93-1.17, $p = 0.46$; keloid: OR = 1.12,
287 95%CI 0.83-1.52, $p = 0.45$; skin fibrosis and scar condition from UKB: OR = 0.95,
288 95%CI 0.39-2.35, $p = 0.30$; skin fibrosis and scar condition from FinnGen: OR = 0.93,
289 95%CI 0.81-1.07, $p = 0.29$). For IVs composed of multiple SNPs proxied serum ACE,
290 results of IVW showed little causal effect on skin fibrotic diseases (hypertrophic scar:
291 OR = 0.96, 95%CI 0.86-1.07, $p = 0.44$; keloid: OR = 1.03, 95%CI 0.78-1.35, $p = 0.49$;
292 skin fibrosis and scar condition from UKB: OR = 0.98, 95%CI 0.90-1.06, $p = 0.56$;
293 skin fibrosis and scar condition from FinnGen: OR = 1.11, 95%CI 0.98-1.25, $p =$
294 0.12). For IVs containing multiple SNPs proxied serum ACE inhibition, we found
295 little causal effect of ACE inhibition on skin fibrotic diseases (hypertrophic scar: OR
296 = 0.998, 95%CI 0.924-1.078, $p = 0.96$; keloid: OR = 1.05, 95%CI 0.85-1.29, $p = 0.66$;
297 skin fibrosis and scar condition from UKB: OR = 0.97, 95%CI 0.91-1.03, $p = 0.33$;
298 skin fibrosis and scar condition from FinnGen: OR = 0.94, 95%CI 0.85-1.03, $p =$
299 0.16). Additionally, other methods also showed little causal relationship between

300 serum ACE or ACE inhibition and skin fibrotic diseases. No significant pleiotropy or
301 heterogeneity bias was observed in these MR analysis (shown in Table 3).

302 **Effect of blood pressure by ACE or ACE inhibition and skin fibrotic diseases**

303 For both IVs of single SNP or multiple SNPs, results of Wald ratio and IVW-FE
304 showed little causal association between the effect of ACE inhibition on decreasing
305 blood pressure by on skin fibrotic diseases (hypertrophic scar, skin fibrosis and scar
306 condition), all the p values were above 0.05 (shown in Table 4 and Figure 2). For MR
307 analysis with IVs containing 2 SNPs, heterogeneity tests showed no significant
308 heterogenetic bias existed in MR analysis (shown in Table 4).

309 **Local ACE expression and skin fibrotic diseases**

310 For skin tissue exposed to or shielded from sunshine exposure, 8 and 11 SNPs was
311 extracted from Qtex datasets respectively to proxy local ACE expression, respectively.
312 Notably, all the p values of SMR analysis were above 0.05 (shown in Table 5), which
313 showed that little causal effect of ACE expression in local skin tissue on susceptibility
314 of skin fibrotic diseases, irrespective of sunshine exposure. All the p values for HEIDI
315 test were above 0.05 (shown in Table 5), which revealed that no significant
316 heterogenetic bias existed.

317 **Systolic and diastolic blood pressure and skin fibrotic diseases**

318 Results of IVW-FE method showed significant negative causal effects of SBP on
319 hypertrophic scar (OR = 0.69, 95% CI 0.54–0.89, p = 0.004). Similarly, results of MR
320 Egger method, and IVW-MRE also demonstrated negative causal effect of SBP on
321 hypertrophic scar, (MR Egger: OR = 0.480, 95% CI 0.244-0.947, p = 0.035;
322 IVW-MRE: OR= 0.69, 95% CI 0.53-0.90, p = 0.007). These results collectively
323 indicated that higher SBP level is causally associated with reduced risk of developing
324 hypertrophic scar. However, IVW and other methods indicated little causal effect of
325 DBP on hypertrophic scar. Additionally, no significant causal relationship was found
326 between SBP or DBP and skin fibrosis and scar condition (shown in Table 6 and
327 Figure 3). Sensitivity tests showed no obvious bias in pleiotropy and heterogeneity.

328 **Effect of other antihypertension drugs and skin fibrotic diseases**

329 Results of IVW-FE revealed obvious positive causal relationship between effect of

330 BBs on decreasing SBP and skin fibrosis and scar condition from FinnGen (OR =
331 1.184, 95%CI 1.033-1.357, $p = 0.015$), which indicated that BBs caused an increase
332 of risk of skin fibrosis. Heterogeneity and pleiotropy tests for both MR analysis
333 showed little heterogeneity and horizontal pleiotropy (shown in Table 7 and Figure 4).
334 However, results of IVW-MRE indicated little causal relationship between effect of
335 BBs on decreasing SBP and hypertrophic scar, for which heterogeneity test revealed
336 significant heterogeneity of this result ($pQ = 0.008$). And results of IVW-FE showed
337 little causal relationship between effects of CCBs on decreasing SBP and hypertrophic
338 scar or skin fibrosis and scar condition, either. Similarly, results of simple mode,
339 weighted mode and weighted median methods for MR analysis showed similar
340 conclusions of the little causal effect of CCBs on hypertrophic scar or skin fibrosis
341 and scar condition. In heterogeneity and pleiotropy test, except MR between BBs and
342 hypertrophic scar, no obvious pleiotropy and heterogeneity bias was observed. Wald
343 ratio results found little causal relationship between blood decreasing effect of ARBs
344 and skin fibrotic diseases (shown in Table 7 and Figure 4).

345

346 **Discussion**

347 Our study found little causal relationship of ACE inhibition on skin fibrotic diseases
348 using two sample MR approach. None of serum ACE, effect of decreasing SBP/DBP
349 by ACE inhibition or local expression of ACE gene in skin tissue was discovered
350 significant with causal association with the occurrence of skin fibrosis and excessive
351 scars including keloid and hypertrophic scar.

352 Nevertheless, a limited number of animal studies have suggested that ACE inhibitors
353 can impede progression of fibrotic skin scars when administered orally or topically,
354 indicating their potential as a therapeutic or preventive agent for such scars.¹¹⁻¹³

355 Additionally, a few case reports,⁴³ the aforementioned retrospective study¹⁴ reported
356 the potential of ACE inhibitor drugs (Enopril and Captopril) treatments for
357 hypertrophic scar and keloid on patients. However, the isolated case reports and
358 retrospective study did not exclude disrupting factors. Moreover, in the retrospective
359 study, utilization of ACE inhibitor and ARB were mixed and the dosage were not

360 unified. The aforementioned clinical trial conducted in Iran¹⁵ demonstrated the
361 effectiveness of tropical ACE inhibitor (Enopril) on decreasing the size of
362 hypertrophic scar. However, there was a lack of large scale clinical researches covered
363 multiple populations which provided evidence for the efficacy of ACE inhibitors in
364 prevention or treatment of skin fibrotic scars.

365 A potential explanation for the discrepancies in the findings lies in the diverse
366 statistical criteria employed to define the outcomes. While animal studies and clinical
367 trials assessed the outcomes based on scar area, our research utilized a GWAS dataset
368 with a binary outcome measure. Our findings indicated that ACE inhibition does not
369 decrease the incidence of skin fibrotic diseases, which is not conflictive with the
370 conclusion that ACE inhibitors have potential to diminish the size of skin fibrotic scar.
371 To the best of our knowledge, there are no quantitative GWAS datasets available with
372 phenotype specially focused on the size of fibrotic scar.

373 Furthermore, the regulation of fibrotic proliferation in tissue by ACE is not a
374 unidirectional process. The products of ACE, angiotensin II, exhibits dual effects on
375 fibrosis. When angiotensin II bind to AT1 receptor, its downstream effect is to
376 promote fibrosis by promoting inflammation reactions such as TGF- β synthesis.
377 When angiotensin II binding to AT2 receptor, it can counteract inflammation reactions
378 and suppress reactions like TGF- β synthesis. Additionally, other downstream products
379 of angiotensin II, such as angiotensin III and angiotensin IV, also have the potential to
380 inhibit fibrosis.^{44, 45}

381 It is noted that the expression of AT1 receptors in skin is comparatively low. RNA seq
382 from normal tissue of different organs indicated that reads per kilobase per million
383 mapped reads (RPKM) of AT1 receptor in skin is 0.906 ± 0.285 , significantly lower
384 than that in other tissues such as liver (21.967 ± 2.326), kidney (5.741 ± 1.363) and
385 heart (2.423 ± 1.416).⁴⁶ These results prompt that the regulation effect by ACE in skin
386 might be less pronounced than that in other tissue or organs.

387 Compared to previous studies, our research had several advantages: 1) Our study
388 provided an exploration of the association between ACE and skin fibrotic diseases
389 with a larger sample scale in European population. 2) Our study design had

390 advantages of eliminating confounding factors as much as possible by pleiotropy test
391 and LD diminishing. 3) Our study investigated the causal relationship beyond merely
392 association relationship by the method of MR analysis.

393 Our research also existed some limitations. The conclusion that ACE inhibition has
394 little causal effect on skin fibrosis was not fully confirmed due to several limitations:
395 1) All the MR analysis were conducted within a single population of European
396 descent. To validate the effect of ACE inhibition on skin fibrotic diseases in other
397 population, GWAS researches from corresponding population were required. 2) The
398 statistical power of MR was insufficient, necessitating GWAS studies of skin fibrotic
399 diseases with larger sample sizes. To the best of our knowledge, exposures for effect
400 of BBs, CCBs and ARBs lacked data of pQTLs of corresponding protein targets, and
401 the analysis primarily included the effects of decreasing blood pressure. Consequently,
402 the direct effects of those protein targets require further research to determine whether
403 significant causal relationship exists between their effects and skin fibrotic diseases.

404

405 **Conclusion**

406 Our findings suggest that ACE inhibitors do not have a direct causal effect on the risk
407 of skin fibrotic diseases, including hypertrophic scars and keloids. This challenges the
408 potential of ACE inhibitors as a therapeutic option for preventing or treating these
409 conditions. Further researches including large scale clinical trials and mechanisms
410 researches are needed to explore the complex interplay between RAS system and skin
411 fibrosis and the potential applications of RAS system on skin fibrotic diseases.

412

413 **Reference**

- 414 1. Jeschke MG, Wood FM, Middelkoop E, et al. Scars. *Nat Rev Dis Primers*.
415 2023;9(1):64. Published 2023 Nov 16. doi:10.1038/s41572-023-00474-x
- 416 2. Ung CY, Warwick A, Onoufriadis A, et al. Comorbidities of Keloid and
417 Hypertrophic Scars Among Participants in UK Biobank. *JAMA Dermatol*.
418 2023;159(2):172-181. doi:10.1001/jamadermatol.2022.5607
- 419 3. Deng CC, Hu YF, Zhu DH, et al. Single-cell RNA-seq reveals fibroblast

- 420 heterogeneity and increased mesenchymal fibroblasts in human fibrotic skin
421 diseases. *Nat Commun.* 2021;12(1):3709. Published 2021 Jun 17.
422 doi:10.1038/s41467-021-24110-y
- 423 4. Lopez-Sublet M, Caratti di Lanzacco L, Danser AHJ, Lambert M, Elourimi G, Persu
424 A. Focus on increased serum angiotensin-converting enzyme level: From
425 granulomatous diseases to genetic mutations. *Clin Biochem.* 2018;59:1-8.
426 doi:10.1016/j.clinbiochem.2018.06.010
- 427 5. Zheng C, Huang L, Luo W, et al. Inhibition of STAT3 in tubular epithelial cells
428 prevents kidney fibrosis and nephropathy in STZ-induced diabetic mice. *Cell Death*
429 *Dis.* 2019;10(11):848. Published 2019 Nov 7. doi:10.1038/s41419-019-2085-0
- 430 6. Russo V, Papa AA, Williams EA, et al. ACE inhibition to slow progression of
431 myocardial fibrosis in muscular dystrophies. *Trends Cardiovasc Med.*
432 2018;28(5):330-337. doi:10.1016/j.tcm.2017.12.006
- 433 7. Shim KY, Eom YW, Kim MY, Kang SH, Baik SK. Role of the renin-angiotensin
434 system in hepatic fibrosis and portal hypertension. *Korean J Intern Med.*
435 2018;33(3):453-461. doi:10.3904/kjim.2017.317
- 436 8. Li S, Zhao W, Tao Y, Liu C. Fugan Wan alleviates hepatic fibrosis by inhibiting
437 ACE/Ang II/AT-1R signaling pathway and enhancing ACE2/Ang 1-7/Mas signaling
438 pathway in hepatic fibrosis rat models. *Am J Transl Res.* 2020;12(2):592-601.
439 Published 2020 Feb 15.
- 440 9. Feng J, Huang X, Xu Q, et al. Pharmacological inhibition of the ACE/Ang-2/AT1
441 axis alleviates mechanical ventilation-induced pulmonary fibrosis. *Int*
442 *Immunopharmacol.* 2024;131:111855. doi:10.1016/j.intimp.2024.111855
- 443 10. Souza-Silva IM, Steckelings UM, Assersen KB. The role of vasoactive peptides in
444 skin homeostasis-focus on adiponectin and the kallikrein-kinin system. *Am J Physiol*
445 *Cell Physiol.* 2023;324(3):C741-C756. doi:10.1152/ajpcell.00269.2022
- 446 11. Fang QQ, Wang XF, Zhao WY, et al. The source of ACE during scar formation is
447 from both bone marrow and skin tissue. *FASEB J.* 2018;32(9):5199-5208.
448 doi:10.1096/fj.201701575RRR
- 449 12. Rha EY, Kim JW, Kim JH, Yoo G. Angiotensin-Converting Enzyme Inhibitor,

- 450 Captopril, Improves Scar Healing in Hypertensive Rats. *Int J Med Sci.*
451 2021;18(4):975-983. Published 2021 Jan 1. doi:10.7150/ijms.50197
- 452 13. Demir CY, Ersoz ME, Erten R, Kocak OF, Sultanoglu Y, Basbugan Y. Comparison
453 of Enalapril, Candesartan and Intralesional Triamcinolone in Reducing Hypertrophic
454 Scar Development: An Experimental Study. *Aesthetic Plast Surg.* 2018;42(2):352-361.
455 doi:10.1007/s00266-018-1073-6
- 456 14. Dow T, Selman T, Williams J, Bezuhly M. The Role of ACE-Inhibitors and ARBs
457 in reducing hypertrophic scarring following bilateral breast reduction. *J Plast*
458 *Reconstr Aesthet Surg.* 2023;78:1-3. doi:10.1016/j.bjps.2022.11.032
- 459 15. Mohammadi AA, Parand A, Kardeh S, Janati M, Mohammadi S. Efficacy of
460 Topical Enalapril in Treatment of Hypertrophic Scars. *World J Plast Surg.*
461 2018;7(3):326-331. doi:10.29252/wjps.7.3.326
- 462 16. Greif T, Alsawas M, Reid AT, et al. Targeting the Angiotensin Pathway in the
463 Treatment of Cutaneous Fibrosis: A Systematic Review. *JID Innov.* 2023;3(6):100231.
464 Published 2023 Sep 12. doi:10.1016/j.xjidi.2023.100231
- 465 17. Bowden J, Holmes MV. Meta-analysis and Mendelian randomization: A review.
466 *Res Synth Methods.* Dec 2019;10(4):486-496. doi:10.1002/jrsm.1346
- 467 18. Lanlan Chen, Stephen Burgess, Shan Luo, Guoyue Lv - First release of Mendelian
468 randomisation book in Chinese: *eGastroenterology* 2023;1:e100043.
- 469 19. Noishiki C, Hayasaka Y, Yoshida R, Ogawa R. Over 90% of Childhood BCG
470 Vaccine-Induced Keloids in Japan Occur in Women. *Dermatol Ther (Heidelb).*
471 2023;13(5):1137-1147. doi:10.1007/s13555-023-00916-0
- 472 20. Arima J, Huang C, Rosner B, Akaishi S, Ogawa R. Hypertension: a systemic key
473 to understanding local keloid severity. *Wound Repair Regen.* 2015;23(2):213-221.
474 doi:10.1111/wrr.12277
- 475 21. Lanlan Chen, Guoyue Lv - New horizons of human genetics in digestive
476 diseases: *eGastroenterology* 2023;1:e100029.
- 477 22. Eldjarn GH, Ferkingstad E, Lund SH, et al. Large-scale plasma proteomics
478 comparisons through genetics and disease associations. *Nature.*
479 2023;622(7982):348-358. doi:10.1038/s41586-023-06563-x

- 480 23. Abdollahi MR, Huang S, Rodriguez S, et al. Homogeneous assay of rs4343, an
481 ACE I/D proxy, and an analysis in the British Women's Heart and Health Study
482 (BWHHS). *Dis Markers*. 2008;24(1):11-17. doi:10.1155/2008/813679
- 483 24. Yarmolinsky J, Díez-Obrero V, Richardson TG, et al. Genetically proxied
484 therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A
485 mendelian randomization analysis. *PLoS Med*. 2022;19(2):e1003897. Published 2022
486 Feb 3. doi:10.1371/journal.pmed.1003897
- 487 25. Kehoe PG, Katzov H, Andreassen N, et al. Common variants of ACE contribute to
488 variable age-at-onset of Alzheimer's disease. *Hum Genet*. 2004;114(5):478-483.
489 doi:10.1007/s00439-004-1093-y
- 490 26. Gill D, Georgakis MK, Koskeridis F, et al. Use of Genetic Variants Related to
491 Antihypertensive Drugs to Inform on Efficacy and Side Effects. *Circulation*.
492 2019;140(4):270-279. doi:10.1161/CIRCULATIONAHA.118.038814
- 493 27. Hanchen Liu, Xiaoxi Zhang, Yu Zhou, Thanh N Nguyen, Lei Zhang, Pengfei Xing,
494 Zifu Li, Hongjian Shen, Yongxin Zhang, Weilong Hua, Hongye Xu, Xuan Zhu, Lei
495 Chen, Qiao Zuo, Rui Zhao, Qiang Li, Dongwei Dai, Yongwei Zhang, Yi Xu, Qinghai
496 Huang, Jianmin Liu, Pengfei Yang, Association between blood pressure and different
497 antihypertensive drugs with outcome after ischemic stroke: A Mendelian
498 randomization study. *International Journal of Stroke*. 2023; 18(10): 1247-1254, doi:
499 10.1177/17474930231185695
- 500 28. Loh PR, Kichaev G, Gazal S, Schoech AP, Price AL. Mixed-model association for
501 biobank-scale datasets. *Nat Genet*. 2018;50(7):906-908.
502 doi:10.1038/s41588-018-0144-6
- 503 29. GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects
504 across human tissues. *Science*. 2020;369(6509):1318-1330.
505 doi:10.1126/science.aaz1776
- 506 30. Kurki MI, Karjalainen J, Palta P, et al. FinnGen provides genetic insights from a
507 well-phenotyped isolated population [published correction appears in Nature. 2023
508 Feb 24;:]. *Nature*. 2023;613(7944):508-518. doi:10.1038/s41586-022-05473-8
- 509 31. Fairley S, Lowy-Gallego E, Perry E, Flicek P. The International Genome Sample

- 510 Resource (IGSR) collection of open human genomic variation resources. *Nucleic*
511 *Acids Res.* 2020;48(D1):D941-D947. doi:10.1093/nar/gkz836
- 512 32. Yao S, Zhang M, Dong SS, et al. Bidirectional two-sample Mendelian
513 randomization analysis identifies causal associations between relative carbohydrate
514 intake and depression. *Nat Hum Behav.* 2022;6(11):1569-1576.
515 doi:10.1038/s41562-022-01412-9
- 516 33. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with
517 multiple genetic variants using summarized data. *Genet Epidemiol.* Nov
518 2013;37(7):658-65. doi:10.1002/gepi.21758
- 519 34. Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic
520 causal inference across the human phenome. *Elife.* 2018;7:e34408. Published 2018
521 May 30. doi:10.7554/eLife.34408
- 522 35. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in
523 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
524 Estimator. *Genet Epidemiol.* May 2016;40(4):304-14. doi:10.1002/gepi.21965
- 525 36. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid
526 instruments: effect estimation and bias detection through Egger regression. *Int J*
527 *Epidemiol.* Apr 2015;44(2):512-25. doi:10.1093/ije/dyv080
- 528 37. Yao S, Zhang M, Dong SS, et al. Bidirectional two-sample Mendelian
529 randomization analysis identifies causal associations between relative carbohydrate
530 intake and depression. *Nat Hum Behav.* 2022;6(11):1569-1576.
531 doi:10.1038/s41562-022-01412-9
- 532 38. Stephen Burgess, H el ene Toin et Cronj e - Incorporating biological and clinical
533 insights into variant choice for Mendelian randomisation: examples and
534 principles: *eGastroenterology* 2024;2:e100042.
- 535 39. Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian
536 randomization studies. *Int J Epidemiol.* Jun 2011;40(3):755-64.
537 doi:10.1093/ije/dyr036
- 538 40. Burgess S. Sample size and power calculations in Mendelian randomization with a
539 single instrumental variable and a binary outcome. *Int J Epidemiol.* Jun

- 540 2014;43(3):922-9. doi:10.1093/ije/dyu005
- 541 41. Zhu Z, Zhang F, Hu H, et al. Integration of summary data from GWAS and eQTL
542 studies predicts complex trait gene targets. *Nat Genet.* 2016; 48 (5):481-487.
543 doi:10.1038/ng.3538
- 544 42. Hedayatyanfard K, Ziai SA, Niazi F, Habibi I, Habibi B, Moravvej H. Losartan
545 ointment relieves hypertrophic scars and keloid: A pilot study. *Wound Repair Regen.*
546 2018; 26 (4):340-343. doi:10.1111/wrr.12648
- 547 43. Ardekani GS, Aghaie S, Nemati MH, Handjani F, Kasraee B. Treatment of a
548 postburn keloid scar with topical captopril: report of the first case [published
549 correction appears in *Plast Reconstr Surg.* 2009 Jun;123(6):1898. Aghaie, Shahin
550 [corrected to Aghaei, Shahin]]. *Plast Reconstr Surg.* 2009; 123 (3):112e-113e.
551 doi:10.1097/PRS.0b013e31819a34db
- 552 44. Silva IMS, Assersen KB, Willadsen NN, Jepsen J, Artuc M, Steckelings UM. The
553 role of the renin-angiotensin system in skin physiology and pathophysiology. *Exp*
554 *Dermatol.* 2020;29(9):891-901. doi:10.1111/exd.14159
- 555 45. Hedayatyanfard K, Haddadi NS, Ziai SA, et al. The renin-angiotensin system in
556 cutaneous hypertrophic scar and keloid formation. *Exp Dermatol.* 2020;29(9):902-909.
557 doi:10.1111/exd.14154
- 558 46. Fagerberg L, Hallström BM, Oksvold P, et al. Analysis of the human
559 tissue-specific expression by genome-wide integration of transcriptomics and
560 antibody-based proteomics. *Mol Cell Proteomics.* 2014; 13 (2):397-406.
561 doi:10.1074/mcp.M113.035600

Table 1 Detailed Information for Exposure GWAS Data

IV	Exposur es	NSN P	R ²	F	Sampl e size	Populatio n	Sourc e
serum_AC E	Serum ACE	30	0.24	376.28	35275	EUR	pQTL of Iceland corhor t
ACE_SBP	ACE effect on SBP	2	6.47e-0 5	30.38	46976 7	EUR	UKB
ACE_DBP	ACE effect on DBP	2	6.43e-0 5	31.53	49046 9	EUR	UKB
serum_AC Ei	Serum ACE inhibitio n	14	0.34-0.3 9	2156.5-2594 .9	4174	EUR	pQTL of GER A
ACEi_SBP	ACE inhibitio n effect on SBP	2	0.28	759.90	75760 1	EUR	UKB and ICBP
SBP	SBP	293	4.37e-0 2	76.66	46976 7	EUR	UKB
DBP	DBP	283	4.56e-0 2	85.79	49046 9	EUR	UKB
Rs4291	ACE inhibitio	1	3.69e-0 4	276.00	74528 0	EUR	UKB and

	n	effect					ICBP
		on SBP					
BB	6	BB effect on SBP	2.54e-04	188.00	73800	EUR	UKB and ICBP
CCB	24	CCB effect on SBP	5.26e-03	176.32	73650	EUR	UKB and ICBP
ARB	1	ARB effect on SBP	3.99e-05	30.25	75760	EUR	UKB and ICBP

GERA: Genetic Epidemiology Research on Adult Health and Aging

ICBP: International Consortium of Blood Pressure-Genome Wide Association Studies

Table 2 Detailed Information for Outcome GWAS Data

Phenotype	UKB-id	Sample size	Ncase	Ncontrol	Source	Population
Hypertrophic scar	-	323,197	1294	321903	Finngen	EUR
Keloid	701.4	404,486	216	402139	UKB	EUR
Skin fibrosis and scar condition	701.2	404,486	2345	402141	UKB	EUR
Skin fibrosis and scar condition	-	322,794	891	321903	Finngen	EUR

Table 3 Serum ACE and Skin Fibrotic Diseases

IV	Exposure	Outcome	Pleiotropy	Heterogeneity	Method	Beta	SE	P-value	OR (95%CI)
rs4343	Serum ACE inhibition	Hypertrophic Scar (FinnGen)	NA	NA	Wald ratio	0.0436	0.0591	0.4607	1.0446 (0.9303-1.1729)
rs4343	Serum ACE inhibition	Keloid (UKB)	NA	NA	Wald ratio	0.1159	0.1540	0.4517	1.1229 (0.8304-1.5184)
rs4343	Serum ACE inhibition	Skin Fibrosis and Scar Condition (UKB)	NA	NA	Wald ratio	-0.0476	0.0460	0.3009	0.9535 (0.8712-1.0435)
rs4343	Serum ACE inhibition	Skin Fibrosis and Scar Condition (FinnGen)	NA	NA	Wald ratio	-0.0747	0.0708	0.2916	0.928 (0.8077-1.0662)

		Hypertrophic Scar (FinnGen)							
serum_ ACE	Serum ACE	Hypertrophic Scar (FinnGen)	0.8122	0.4179	IVW-	-0.0	0.0	0.44	0.9596
					FE	412	538	36	(0.8636-
									1.0663)
					IVW-	-0.0	0.0	0.45	0.9596
					MRE	412	546	07	(0.8622-
									1.0681)
					Weighted				1.026
					Median	56	765	75	(0.8831-
									1.192)
					Simplified	0.06	0.1	0.58	1.072
Mode	95	245	08	(0.8399-					
				1.3682)					
Weighted				1.0147					
Mode	0.01	0.0	0.84	(0.8792-					
	46	732	30	1.1712)					
serum_ ACE	Serum ACE	Keloid (UKB)	0.8346	0.9486	IVW-	0.02	0.1	0.84	1.0276
					FE	72	387	43	(0.783-1.
									3487)
					IVW-	0.02	0.1	0.80	1.0276
					MRE	72	086	20	(0.8306-
									1.2714)
					Weighted				1.1397
					Median	0.13	0.1	0.49	(0.7855-
						08	899	09	1.6536)
					Simplified	-0.1	0.3	0.71	0.881

		Condi tion (FinnG en)							
				IVW-	0.10	0.0	0.05	1.1055	
				MRE	03	518	26	(0.9989- 1.2236)	
				Weig hted	0.05	0.0	0.50	1.0589	
				Media n	72	864	78	(0.8939- 1.2544)	
				Simpl e Mode	-0.0 115	0.1 317	0.93 12	0.9886 (0.7637- 1.2797)	
				Weig hted Mode	0.04 13	0.0 838	0.62 56	1.0422 (0.8844- 1.2282)	
serum_ ACEi	Seru m ACE inhibi tion	Hypert rophic Scar (FinnG en)	0.6886	0.4511	IVW- FE	-0.0 019	0.0 394	0.96 07	0.9981 (0.9238- 1.0783)
					IVW- MRE	-0.0 019	0.0 393	0.96 06	0.9981 (0.924-1. 078)
				Weig hted Media n	-0.0 199	0.0 504	0.69 32	0.9803 (0.8881- 1.0821)	

					Simpl				0.8812
					e	-0.1	0.0	0.17	(0.7428-
					Mode	264	872	26	1.0454)
					Weig				1.0142
					hted	0.01	0.0	0.80	(0.9097-
					Mode	41	555	37	1.1307)
	Seru								
	m								1.0476
serum_	ACE	Keloid	0.6304	0.6612	IVW-	0.04	0.1	0.66	(0.8503-
ACEi	inhibi	(UKB)			FE	65	064	24	1.2906)
	tion								
					IVW-	0.04	0.0	0.62	1.0476
					MRE	65	952	54	(0.8693-
									1.2625)
					Weig				1.1189
					hted	0.11	0.1	0.39	(0.8619-
					Media	24	331	87	1.4525)
					n				
					Simpl				1.0277
					e	0.02	0.2	0.90	(0.6535-
					Mode	73	310	77	1.6163)
					Weig				1.1197
					hted	0.11	0.1	0.45	(0.8417-
					Mode	30	456	14	1.4894)
	Seru	Skin							
	m	Fibrosi							0.9693
serum_	ACE	s and	0.6263	0.13664	IVW-	-0.0	0.0	0.33	(0.9102-
ACEi	inhibi	Scar	33556	7881	FE	311	321	21	1.0323)
	tion	Condi							

	n			
Simpl		0.01	0.1	0.89
e	34	012	70	1.0135
Mode				(0.8311- 1.2358)
Weig		-0.0	0.0	0.51
hted	428	640	67	0.9581
Mode				(0.8452- 1.0862)

Table 4 ACE Effect on Blood Pressure and Skin Fibrotic Diseases

IV	Exposure	Outcome	Pleiotropy	Heterogeneity	Method	Beta	SE	P-value	OR (95%CI)
rs4291	Effect of ACE inhibition on SBP	Hypertrophic Scar (FinnGen)	NA	NA	Wald ratio	0.0717	0.1338	0.5922	1.0743 (0.8264-1.3965)
rs4291	Effect of ACE inhibition on SBP	Skin Fibrosis and Scar Condition (FinnGen)	NA	NA	Wald ratio	0.1193	0.1604	0.4568	1.1268 (0.8228-1.5429)
ACE_SBP	Effect of ACE inhibition on SBP	Hypertrophic Scar (FinnGen)	NA	NA	Wald ratio	1.7460	3.1452	0.5788	5.7315 (0.0121-2725.9807)
ACE_SBP	Effect of ACE inhibition on SBP	Skin Fibrosis and Scar Condition	NA	NA	Wald ratio	5.1906	3.7723	0.1688	179.5763 (0.1105-291939.3434)

		(FinnG en)							
	Effec t of	Hypert rophic							5.7621
ACE_ DBP	ACE on	Scar (FinnG en)	NA	NA	Wald ratio	1.7 513	3.1 548	0.57 88	(0.0119-279 2.3439)
		Skin							
	Effec t of	Fibrosi s and							182.433
ACE_ DBP	ACE on	Scar Condi on (FinnG en)	NA	NA	Wald ratio	5.2 064	3.7 838	0.16 88	(0.1097-303 326.6091)
	Effec t of	Hypert rophic							1.0948
ACEi _SBP	ACE inhib ition on	Scar (FinnG en)	NA	0.8594	IVW- FE	0.0 905	0.1 192	0.44 75	(0.8667-1.3 829)
		SBP							1.0948
					IVW- MRE	0.0 905	0.0 211	0.00 00	(1.0504-1.1 41)
	Effec t of	Skin Fibrosi s and							1.2292
ACEi _SBP	ACE inhib	Scar	NA	0.4739	IVW- FE	0.2 063	0.1 429	0.14 88	(0.9289-1.6 265)

ition Condi
on on
SBP (FinnG
en)

				1.2292
IVW-	0.2	0.1	0.04	(1.0057-1.5
MRE	063	023	38	022)

Table 5 ACE Expression in Local Skin Tissue and Skin Fibrotic Diseases

Tissue	Outcome	Gene	Probe _bp	Top snp	A 1	A 2	Fr eq	B_s mr	Se_ smr	P_s mr	P_h eidi	NSNP_ heidi
Supra pubic skin	Hypetr ophic scar	A CE	6155 4422	Rs4 311	C	T	0. 50	-0.1 3	0.23	0.5 8	0.77	8
Supra pubic skin	Keloid	A CE	6155 4422	Rs4 311	C	T	0. 50	-0.6 3	0.62	0.3 1	0.95	8
Supra pubic skin	and scar conditi on (UKB) Skin fibrosis	A CE	6155 4422	Rs4 311	C	T	0. 50	0.0 6	0.18	0.7 6	0.47	8
Supra pubic skin	and scar conditi on (Finng en)	A CE	6155 4422	Rs4 311	C	T	0. 50	0.1 8	0.28	0.5 3	0.88	8
Leg	Hypetr ophic scar	A CE	6155 4422	Rs4 292	T	C	0. 63	0.1 4	0.21	0.5 0	0.22	11
Leg	Keloid	A CE	6155 4422	Rs4 292	T	C	0. 63	-0.3 6	0.55	0.5 2	1.00	11

Table 6 Blood Pressure and Skin Fibrotic Diseases

IV	Exposure	Outcome	Pleiotropy	Heterogeneity	Method	Beta	SE	P-value	OR (95%CI)
SBP	SBP	Hypertrophic Scar (FinnGen)	0.2526	0.0588	IVW-	-0.3	0.1	0.00	0.6925
					FE	675	269	38	(0.54-0.881)
					IVW-	-0.3	0.1	0.00	0.6925
					MRE	675	353	66	(0.5312-0.9028)
					Weighted	-0.3	0.2	0.08	0.6981
					Median	594	090	55	(0.4635-1.0515)
SBP	SBP	Skin Fibrosis and Scar Condition (FinnGen)	0.1628	0.6433	Simple	-0.6	0.6	0.32	0.5372
					Mode	215	273	27	(0.1571-1.8368)
					Weighted	-0.4	0.4	0.31	0.6254
					Mode	694	676	63	(0.2501-1.5637)
					IVW-	-0.1	0.1	0.46	0.8953
					FE	106	519	65	(0.6647-1.2058)

Table 7 Other Antihypertension Drugs' Effect on Blood Pressure and Skin Fibrotic Diseases

IV	Exposure	Outcome	Pleiotropy	Heterogeneity	Method	Beta	SE	P-value	OR (95%CI)
A R B	Effect of ARBs on SBP	Hypertrrophic Scar (FinnGen)	NA	NA	Wald ratio	-0.1505	0.2000	0.4940	0.8603
									(0.5589-1
									.3241)
A R B	Effect of ARBs on SBP	Fibrosis and Scar Condition (FinnGen)	NA	NA	Wald ratio	0.3220	0.2638	0.2222	1.3799
									(0.8228-2
									.3142)
B B	Effect of BBs on SBP	Hypertrrophic Scar (FinnGen)	0.4511	0.0085	IVW-FE	0.0627	0.0583	0.2821	1.0648
									(0.9497-1
									.1938)
					IVW-	0.06	0.1	0.54	1.0648
					MRE	27	027	12	(0.8706-1
									.3022)
					Weighted	0.01	0.0	0.84	1.0152
					Median	50	763	37	(0.8741-1
					n				.179)

					Simple	0.05	0.1	0.65	1.0514
					Mode	01	072	98	(0.8522-1
									.2971)
					Weigh				0.9777
					ted	-0.0	0.0	0.79	(0.8321-1
					Mode	226	822	47	.1487)
		Skin							
		Fibrosis							
	Effect	and							
	of	Scar			IVW-	0.16	0.0	0.01	1.1839
B	BBs	Condi	0.7791	0.6579	FE	88	696	53	(1.033-1.
B	on	on							3569)
	SBP	(FinnGe							
		n)							
					IVW-	0.16	0.0	0.00	1.1839
					MRE	88	563	27	(1.0602-1
									.3221)
					Weigh				1.1622
					ted	0.15	0.0	0.06	(0.9883-1
					Media	03	827	91	.3667)
					n				
					Simple	0.18	0.1	0.21	1.1982
					Mode	08	287	91	(0.931-1.
									5421)
					Weigh				1.1614
					ted	0.14	0.0	0.18	(0.9614-1
					Mode	96	964	15	.4031)
C	Effect	Hypertr			IVW-	0.05	0.0	0.06	1.0605
C	of	ophic	0.3079	0.5962	FE	88	322	84	(0.9956-1

B	CCBs	Scar							.1297)
	on	(FinnGe							
	SBP	n)							
					IVW-	0.05	0.0	0.05	1.0605
					MRE	88	305	43	(0.9989-1
									.1259)
					Weigh				
					ted	0.06	0.0	0.12	1.0717
					Media	93	447	12	(0.9818-1
					n				.1699)
					Simple	0.11	0.0	0.18	1.1168
					Mode	05	813	84	(0.9524-1
									.3097)
					Weigh				1.0829
					ted	0.07	0.0	0.21	(0.9574-1
					Mode	96	628	88	.2248)
		Skin							
		Fibrosis							
	Effect	and							
C	of	Scar			IVW-	-0.0	0.0	0.14	0.946
C	CCBs	Condi	0.7805	0.3859	FE	556	386	99	(0.8771-1
B	on	on							.0203)
	SBP	(FinnGe							
		n)							
					IVW-	-0.0	0.0	0.16	0.946
					MRE	556	397	17	(0.8751-1
									.0225)
					Weigh	-0.0	0.0	0.23	0.937
					ted	651	549	54	(0.8415-1

Media				.0433)
n				
Simple	-0.0	0.0	0.51	0.9456
Mode	559	850	81	(0.8005-1
				.1171)
Weigh				0.9327
ted	-0.0	0.0	0.28	(0.8247-1
Mode	696	628	00	.0549)







